

HR 5304

PBM Transparency in Prescription Drug Costs Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Dec 4, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Dec 5, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/5304>

Sponsor

Name: Rep. Schrader, Kurt [D-OR-5]

Party: Democratic • **State:** OR • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Gianforte, Greg [R-MT-At Large]	R · MT		Dec 4, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Dec 5, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 4796	Related bill	Oct 5, 2020: Read twice and referred to the Committee on Finance.
116 HR 8527	Related bill	Oct 2, 2020: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, the Judiciary, Oversight and Reform, House Administration, Rules, the Budget, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
116 S 1895	Related bill	Jul 8, 2019: Placed on Senate Legislative Calendar under General Orders. Calendar No. 133.

PBM Transparency in Prescription Drug Costs Act

This bill requires group health plans or the pharmacy benefits manager (PBM) for the plans to periodically report certain prescription drug pricing and utilization data; it also requires PBMs to pass on to health plans all rebates and discounts received from drug manufacturers.

Actions Timeline

- **Dec 5, 2019:** Referred to the Subcommittee on Health.
- **Dec 4, 2019:** Introduced in House
- **Dec 4, 2019:** Referred to the House Committee on Energy and Commerce.